ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RNAC vs UPB // REVENUE GROWTH (YOY)

Cartesian Therapeutics Inc. (NASDAQ) VS. Upstream Bio Inc. (NASDAQ) • 15-METRIC TALLY: RNAC 2 — UPB 3
▲ REVENUE GROWTH (YOY) LEADER: UPB
revenue-growth
20.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RNAC VS. UPB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RNAC UPB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE -65.00% 20.40% -85.40 UPB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 6.01 -5.81 UPB /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 UPB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.2 39.5 +0.70 RNAC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $191.8M $183.5M $8.3M RNAC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RNAC REV UPB REV RNAC GROSS % UPB GROSS % RNAC FCF UPB FCF
FY 2025 $400.0K $2.9M — — -$79.4M -$133.4M
FY 2024 $38.3M $2.4M — — -$32.8M -$59.7M
FY 2023 $26.0M $2.4M — — -$51.2M -$37.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RNAC // BETA —
UPB // BETA —